PeproMene Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PeproMene Bio, Inc. - overview
Established
2017
Location
Irvine, CA, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in California, US, PeproMene Bio, Inc. develops therapies for B-cell malignancies. In December 2024, PeproMene Bio. Inc.
raised USD 11 million in venture funding from the Institute for Follicular Lymphoma Innovation. As of 2024, the company is led by its CEO, Paul Y. Song. PeproMene Bio specializes in therapies aimed at cancers and immune disorders, with a primary focus on PMB-CT01, a BAFF-R-targeted CAR T cell therapy.
This therapy targets the B-cell Activating Factor Receptor (BAFF-R) on B cells, offering potential solutions for B-cell malignancies. The firm’s product portfolio includes BAFF-R bispecific T cell engagers and BAFF-R CAR NK cells, which are in clinical trials in the United States for relapsed or refractory B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. The end users are oncologists and hematologists. The company’s revenue model is driven by partnerships and clinical trial engagements with research institutions and healthcare providers focused on B-cell malignancies.
Revenue generation occurs through collaborative agreements involving clinical trial funding, milestone payments, and potential royalties from future product sales. The organization plans to use the December 2024 funding to accelerate the research and development of its product.
Current Investors
Institute for Follicular Lymphoma Innovation
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.pepromenebio.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.